9,011 results match your criteria Thrombolytic Therapy in Stroke


Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.

J Neurol Sci 2019 Jan 29;399:76-81. Epub 2019 Jan 29.

School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan; Department of Public Health, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:

Background And Purpose: The optimal dose of alteplase for acute ischemic stroke among geriatric patients is unclear. We aimed to assess the efficacy and safety of a low-dose (0.6 mg/kg) and standard-dose (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.01.047DOI Listing
January 2019

Comparison of myocardial microcirculatory perfusion after catheter-administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST-elevation myocardial infarction.

Catheter Cardiovasc Interv 2019 Feb 17. Epub 2019 Feb 17.

Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Objective: To evaluate efficacy, safety and feasibility of targeted intracoronary injection using pro-urokinase combined with anisodamine (TCA) versus thrombus aspiration (TA) in ST-elevation myocardial infarction (STEMI) patients with high thrombus loads.

Background: The best method of avoiding thrombus detachment and stroke in PCI patients with high thrombus loads has not yet been established.

Methods: STEMI patients receiving coronary artery angiography or percutaneous coronary intervention (CAG/PCI) with thrombus grade ≥ 3 from January 1, 2017 to June 30, 2018 were randomly assigned to targeted intracoronary thrombolysis (pro-urokinase and anisodamine via catheter (TCA) group), or the TA group which followed the standard thrombus aspiration procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.28112DOI Listing
February 2019

Atypical Thrombotic Thrombocytopenic Purpura Presenting as Stroke.

Case Rep Hematol 2019 14;2019:7425320. Epub 2019 Jan 14.

Division of Hematology, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, 6411 Fannin Street, Houston 77030, USA.

Here we report a case of atypical thrombotic thrombocytopenic purpura that presented as an ischemic cerebrovascular accident. A 56-year-old man with multiple cardiovascular risk factors presented with sudden left-sided weakness, slurred speech, and left facial droop. He showed mild improvement when he was treated with thrombolytic therapy according to the hospital stroke protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7425320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350572PMC
January 2019
1 Read

Time Is Brain.

Stroke 2019 Feb 14:STROKEAHA118024214. Epub 2019 Feb 14.

From the Institute and Policlinic of Diagnostic and Interventional Neuroradiology, University Hospital Carl Gustav Carus, Dresden,Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.024214DOI Listing
February 2019

Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.

J Vasc Interv Neurol 2018 Nov;10(2):15-17

Stroke Unit, Department of Neuroscience, AOU Sassari, Italy.

Introduction: Dabigatran is one of the nonvitamin K antagonist oral anticoagulants. Thrombolytic treatment with intravenous recombinant tissue plasminogen activator is contraindicated in patients taking a DOAC. Idarucizumab was recently approved for dabigatran-activity reversing in severe bleeding, emergency surgery, or urgent procedures, but many attempts have been made to use idarucizumab in patients presenting with acute ischemic stroke in order to be eligible for thrombolysis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350876PMC
November 2018
7 Reads

Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.

Lancet 2019 Feb 6. Epub 2019 Feb 6.

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, The Glenfield Hospital, Leicester, UK.

Background: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke.

Methods: We did an international, partial-factorial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age ≥18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were screened at 110 sites in 15 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)30038-8DOI Listing
February 2019
1 Read

Association of Elevated Blood Pressure Levels with Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.

J Stroke 2019 Jan 31;21(1):78-90. Epub 2019 Jan 31.

Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Background And Purpose: Although arbitrary blood pressure (BP) thresholds exist for acute ischemic stroke (AIS) patients eligible for intravenous thrombolysis (IVT), current international recommendations lack clarity on the impact of mean pre- and post-IVT BP levels on clinical outcomes.

Methods: Eligible studies involving IVT-treated AIS patients were identified that reported the association of mean systolic BP (SBP) or diastolic BP levels before and after IVT with the following outcomes: 3-month favorable functional outcome (modified Rankin Scale [mRS] scores of 0-1) and 3-month functional independence (mRS scores of 0-2), 3-month mortality and symptomatic intracranial hemorrhage (sICH). Unadjusted analyses of standardized mean differences and adjusted analyses of studies reporting odds ratios (ORadj) per 10 mm Hg BP increment were performed using random-effects models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5853/jos.2018.02369DOI Listing
January 2019
1 Read

Visualizing the Distribution of Matrix Metalloproteinases in Ischemic Brain Using In Vivo F-Magnetic Resonance Spectroscopic Imaging.

Contrast Media Mol Imaging 2019 6;2019:8908943. Epub 2019 Jan 6.

Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata, Niigata, Japan.

Matrix metalloproteinases (MMPs) damage the neurovascular unit, promote the blood-brain barrier (BBB) disruption following ischemic stroke, and play essential roles in hemorrhagic transformation (HT), which is one of the most severe side effects of thrombolytic therapy. However, no biomarkers have presently been identified that can be used to track changes in the distribution of MMPs in the brain. Here, we developed a new F-molecular ligand, TGF-019, for visualizing the distribution of MMPs in vivo using F-magnetic resonance spectroscopic imaging (F-MRSI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8908943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339703PMC
January 2019
1 Read

Combined application of hypothermia and medical gases in cerebrovascular diseases.

Med Gas Res 2018 Oct-Dec;8(4):172-175. Epub 2019 Jan 9.

Department of Neurosurgery & Brain and Nerve Research Laboratory, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.

Cerebrovascular diseases have a heavy burden on society and the family. At present, in the treatment of cerebrovascular diseases, the recognized effective treatment method is a thrombolytic therapy after cerebral infarction, but limited to the time window problem, many patients cannot benefit. Other treatments for cerebrovascular disease are still in the exploration stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2045-9912.248269DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352567PMC
January 2019
1 Read

Timing of Anticoagulation in Atrial Fibrillation Status Post Cardioembolic Stroke.

J Pharm Pract 2019 Jan 31:897190019825577. Epub 2019 Jan 31.

2 Pharmacy Practice Department, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.

Background:: Anticoagulation is the mainstay of secondary stroke prevention in patients with atrial fibrillation; however, few studies have assessed the optimal timing for initiation of anticoagulation post cardioembolic stroke. In the 2 weeks following an acute cardioembolic stroke, the risk of recurrent stroke is as high as 8%, but this risk must be balanced against the risk of hemorrhagic transformation with early initiation of anticoagulation.

Purpose:: This study described the time to initiation of anticoagulation and evaluated the in-hospital incidence of hemorrhagic and ischemic complications in 106 patients with atrial fibrillation post an acute cardioembolic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0897190019825577DOI Listing
January 2019
5 Reads

The safety and efficacy of tPA intravenous thrombolysis for treating acute ischemic stroke patients with a history of cerebral hemorrhage.

Braz J Med Biol Res 2019 Jan 24;52(2):e7739. Epub 2019 Jan 24.

Department of Neurology, The Second Hospital of Shandong University, Jinan, Shandong, China.

Alteplase (tPA) intravenous thrombolysis is an effective treatment for acute ischemic stroke (AIS) when administered within 4.5 h of initial stroke symptoms. Here, its safety and efficacy were evaluated among AIS patients with a previous history of cerebral hemorrhage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431X20187739DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345357PMC
January 2019

Effects of thrombolysis within 6 hours on acute cerebral infarction in an improved rat embolic middle cerebral artery occlusion model for ischaemic stroke.

J Cell Mol Med 2019 Jan 29. Epub 2019 Jan 29.

Department of Neurology, Shandong Provincial Qianfoshan Hospital, Affiliated to Shandong University, Jinan, Shandong, China.

Recombinant tissue plasminogen activator (rt-PA) is the first-line drug for revascularization in acute cerebral infarction (ACI) treatment. In this study, an improved rat embolic middle cerebral artery occlusion model for ischaemic stroke was used and the rats were killed on the first, third and seventh day after model establishment. Increases in infarct volume were significantly less in the thrombolytic group than in the conventional group at every time-point. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jcmm.14120
Publisher Site
http://dx.doi.org/10.1111/jcmm.14120DOI Listing
January 2019
4 Reads

Fast-tracking acute stroke care in China: Shenzhen Stroke Emergency Map.

Postgrad Med J 2019 Jan 29. Epub 2019 Jan 29.

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China

China has the largest stroke population and at-risk population in the world. However, it has a lower thrombolytic therapy rate and longer onset-to-needle time/door-to-needle time for patients who had an acute stroke compared with developed countries, which might be due to redundant procedures or inefficient systems. Things are changing due to some new initiatives. Read More

View Article

Download full-text PDF

Source
http://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2018-1361
Publisher Site
http://dx.doi.org/10.1136/postgradmedj-2018-136192DOI Listing
January 2019
3 Reads

Acute alcohol intoxication may cause delay in stroke treatment - case reports.

BMC Neurol 2019 Jan 29;19(1):14. Epub 2019 Jan 29.

Department of Neurology, Faculty of Medicine, University of Debrecen, Moricz Zs. krt 22, Debrecen, 4032, Hungary.

Background: The signs and symptoms of acute alcohol intoxication resemble those of vertebrobasilar stroke. Due to their shared symptoms including double vision, nystagmus, dysarthria, and ataxia, the differential diagnosis of alcohol intoxication and vertebrobasilar stroke may pose a challenge. Moreover, if alcohol intoxication and stroke occur simultaneously, the signs and symptoms of stroke may be attributed to the effects of alcohol, leading to delayed stroke diagnosis and failure to perform reperfusion therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-019-1241-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350361PMC
January 2019
1 Read

Innovations in Acute Stroke Reperfusion Strategies.

Ann Indian Acad Neurol 2019 Jan-Mar;22(1):6-12

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Vascular neurology is witnessing unprecedented innovations in the management of acute ischemic stroke, especially in reperfusion strategies. The emergence of mechanical thrombectomy with new generation devices has revolutionized the treatment of acute ischemic stroke with large vessel occlusion. The reperfusion strategies are evolving with the extension of the window period for thrombolysis and endovascular therapy through the concept of "tissue clock" in addition to the established "time clock. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/aian.AIAN_263_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327700PMC
January 2019
3 Reads

Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.

Am J Health Syst Pharm 2019 Feb;76(4):211-213

Department of Pharmacy, Wesley Medical Center, Wichita, KS.

Purpose: A case of alteplase administration to a patient with vasculitis and acute ischemic stroke (AIS) is reported.

Summary: A 38-year-old woman with a recent diagnosis of granulomatosis with polyangiitis (GPA) received alteplase for AIS and developed symptomatic hemorrhagic conversion. Published reports regarding the safety of thrombolytic therapy in patients with a high inflammatory burden are inconsistent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/zxy048DOI Listing
February 2019
1 Read

Efficacy of Sonothrombolysis Using Microbubbles Produced by a Catheter-Based Microfluidic Device in a Rat Model of Ischemic Stroke.

Ann Biomed Eng 2019 Jan 28. Epub 2019 Jan 28.

Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.

Limitations of existing thrombolytic therapies for acute ischemic stroke have motivated the development of catheter-based approaches that utilize no or low doses of thrombolytic drugs combined with a mechanical action to either dissolve or extract the thrombus. Sonothrombolysis accelerates thrombus dissolution via the application of ultrasound combined with microbubble contrast agents and low doses of thrombolytics to mechanically disrupt the fibrin mesh. In this work, we studied the efficacy of catheter-directed sonothrombolysis in a rat model of ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10439-019-02209-0DOI Listing
January 2019
2 Reads
3.195 Impact Factor

Dynamic Detection of Thrombolysis in Embolic Stroke Rats by Synchrotron Radiation Angiography.

Transl Stroke Res 2019 Jan 24. Epub 2019 Jan 24.

Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.

A rodent model of embolic middle cerebral artery occlusion is used to mimic cerebral embolism in clinical patients. Thrombolytic therapy is the effective treatment for this ischemic injury. However, it is difficult to detect thrombolysis dynamically in living animals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12975-019-0687-6DOI Listing
January 2019
1 Read

Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.

J Stroke Cerebrovasc Dis 2019 Jan 14. Epub 2019 Jan 14.

Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, China. Electronic address:

Objective: To evaluate the efficacy of tirofiban administered at different time points within 24 hours of intravenous thrombolysis with alteplase in acute ischemic stroke.

Methods: Patients who underwent intravenous thrombolysis with alteplase and fulfilled other inclusion criteria were randomly divided into 4 groups according to the time points of tirofiban administration: Group A (2 h), Group B (2-12 h), Group C (12-24 h), and Group D (control). The changes in National Institutes of Health Stroke Scale score, modified Rankin Scale score, and adverse events were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.12.044DOI Listing
January 2019
2 Reads

Thrombolysis Therapy in Specialized and Non-specialized Stroke Units.

Arch Med Res 2019 Jan 12. Epub 2019 Jan 12.

University of South Carolina, School of Medicine, Greenville, SC, USA. Electronic address:

Background: The benefits of a special stroke care unit (SSCU) over a non-specialized stroke care unit (NSSCU) is well documented in the literature. However, there are concerns that the benefits seen in the SSCU do not consider clinical risk factors that affect thrombolysis therapy.

Method: Retrospective data were collected from a stroke registry between January 1, 2010-June 30, 2016. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01884409183074
Publisher Site
http://dx.doi.org/10.1016/j.arcmed.2019.01.002DOI Listing
January 2019
4 Reads

Futile reperfusion and predicted therapeutic benefits after successful endovascular treatment according to initial stroke severity.

BMC Neurol 2019 Jan 15;19(1):11. Epub 2019 Jan 15.

Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea.

Background: Futile reperfusion (poor functional status despite successful reperfusion) was observed in up to 67% of patients enrolled in recent endovascular treatment (EVT) clinical trials. We investigated the impact of baseline stroke severity on both futile reperfusion and therapeutic benefit of successful EVT.

Methods: Using a prospective multicenter stroke registry, we identified consecutive ischemic stroke patients with anterior circulation large artery occlusion, who were reperfused successfully by EVT (Thrombolysis in Cerebral Infarction grade 2b-3). Read More

View Article

Download full-text PDF

Source
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-
Publisher Site
http://dx.doi.org/10.1186/s12883-019-1237-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332890PMC
January 2019
6 Reads

Nucleic Acid Therapies for Ischemic Stroke.

Neurotherapeutics 2019 Jan 11. Epub 2019 Jan 11.

Division of Neurocritical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.

Stroke remains a leading cause of disability and death worldwide despite significant scientific and therapeutic advances. Therefore, there is a critical need to improve stroke prevention and treatment. In this review, we describe several examples that leverage nucleic acid therapeutics to improve stroke care through prevention, acute treatment, and recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00710-xDOI Listing
January 2019
2 Reads

The rate of early neurological deterioration occurring after thrombolytic therapy: A meta-analysis.

Brain Behav 2019 Feb 10;9(2):e01210. Epub 2019 Jan 10.

The Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang, China.

Objectives: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta-analysis was conducted in the present study.

Methods: The relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/brb3.1210
Publisher Site
http://dx.doi.org/10.1002/brb3.1210DOI Listing
February 2019
5 Reads

Intra-arterial administration of cell-based biological agents for ischemic stroke therapy.

Expert Opin Biol Ther 2019 Mar 21;19(3):249-259. Epub 2019 Jan 21.

a 2nd Department of Radiology, Division of Interventional Radiology, School of Medicine , National and Kapodistrian University of Athens, Attikon University Hospital , Athens , Greece.

Introduction: Ischemic stroke is becoming a primary cause of disability and death worldwide. To date, therapeutic options remain limited focusing on mechanical thrombolysis or administration of thrombolytic agents. However, these therapies do not promote neuroprotection and neuro-restoration of the ischemic area of the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566454DOI Listing
March 2019
3 Reads

Timeliness of Nursing Care Delivered by Stroke Certified Registered Nurses as Compared to Non-Stroke Certified Registered Nurses to Hyperacute Stroke Patients.

J Neurosci Nurs 2019 Feb;51(1):54-59

Questions or comments about this article may be directed to Janet M. Lakomy, PhD RN, at She is an Adjunct Faculty, Texas A&M University, Texarkana, TX. Grace N. Fant, MSN RN SCRN, CHRISTUS St. Michael Health System, Texarkana, TX.

In this retrospective, nonexperimental, comparative descriptive design using convenience sampling, the timeliness of care delivered by 11 Stroke Certified Registered Nurses (SCRNs) to 95 hyperacute stroke patients (last known well of 4.5 hours or less) on the acute stroke protocol set by Target: Stroke Phase II Campaign Manual was compared with that of 13 non-SCRNs in a small, rural, level III stroke facility in the southwestern region of the United States. There was statistical significance in the total timeliness of care delivered by SCRNs to hyperacute stroke patients as compared with the non-SCRNs (t = -4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JNN.0000000000000414DOI Listing
February 2019
4 Reads

Causes of delayed arrival with acute ischemic stroke beyond the window period of thrombolysis.

J Family Med Prim Care 2018 Nov-Dec;7(6):1248-1252

Department of Neurology, Sri Ramachandra Medical College, Chennai, Tamil Nadu, India.

Context: Early thrombolytic therapy in acute ischemic stroke has proven to reduce the associated morbidity. Many factors are in play, delaying the arrival of patients.

Aim: To ascertain the factors causing delay in patients with acute ischemic stroke presenting beyond the window period of thrombolysis in and around Chennai, Tamil Nadu, India. Read More

View Article

Download full-text PDF

Source
http://www.jfmpc.com/text.asp?2018/7/6/1248/246446
Publisher Site
http://dx.doi.org/10.4103/jfmpc.jfmpc_122_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293923PMC
January 2019
7 Reads

Effect of Pretreatment Blood Pressure on Outcomes in Thrombolysed Acute Ischemic Stroke Patients: A Systematic Review and Meta-analysis.

J Stroke Cerebrovasc Dis 2019 Jan 3. Epub 2019 Jan 3.

Yong Loo Lin School of Medicine, National University of Singapore; Division of Neurology, Department of Medicine, National University Health System. Electronic address:

Background: Blood pressure (BP) is an important determinant of functional outcome in acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (IV-tPA). Current guidelines recommend a BP target of 185/110 mmHg before IV-tPA bolus and maintaining it at less than 180/105 mmHg for the first 24 hours. However, the effect of blood pressure on various outcome measures after systemic thrombolysis remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.12.008DOI Listing
January 2019
3 Reads
1.993 Impact Factor

Optimal treatment modality for coexisting acute myocardial infarction and ischemic stroke.

Am J Emerg Med 2018 Dec 31. Epub 2018 Dec 31.

Department of Neurology, Harran University School of Medicine Hospital, Sanliurfa, Turkey.

The simultaneous occurrence of acute ST-segment elevation myocardial infarction and acute ischemic stroke is an uncommon and complex clinical presentation. Although the medical treatment of both diseases is similar, data regarding optimal reperfusion therapy are limited. Nevertheless, use of tissue plasminogen activator may be a reasonable strategy for treatment of both diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajem.2018.12.060DOI Listing
December 2018
3 Reads

Talk About Thrombolysis. Regular Case-Based Discussions of Stroke Thrombolysis Improve Door-to-Needle Time by 20%.

J Stroke Cerebrovasc Dis 2018 Dec 28. Epub 2018 Dec 28.

Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany; Biomagnetic Center, University Hospital, Germany. Electronic address:

Background: The outcome of stroke patients can be improved by a rapid initiation of thrombolytic therapy. Here, we sought to determine whether an additional simple but thorough case-based discussion of recent thrombolysed cases with the entire neurologic staff can improve the door-to-needle time without changes to the implemented stroke protocol.

Methods: For every performed thrombolysis, a route card, consisting of a timeline with 3 time points and target times, had to be completed by the attending neurologist. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10523057183070
Publisher Site
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.12.002DOI Listing
December 2018
2 Reads

The efficacy and safety of thrombolytic agents for patients with cerebral infarction: A protocol for systematic review and network meta-analysis.

Medicine (Baltimore) 2018 Dec;97(52):e13762

Department of Encephalopathy, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.

Background: Cerebral infarction is a commonly dangerous disease also with high morbidity and mortality. Thrombolytic agent is an effective method to treat it, but their relative efficacy and safety are unclear. A network meta-analysis (NMA) will be conducted to resolve this urgent problem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314708PMC
December 2018
2 Reads

Concomitant embolism in the subclavian and pulmonary artery.

Rozhl Chir 2018 ;97(10):478-481

Introduction: Pulmonary embolism is a life-threatening condition that causes obstruction of the pulmonary arteries by an embolus, most often originating from the venous system of the lower limbs or pelvic veins. Depending on the extent of the embolism, an acute right-sided heart failure may result, with subsequent death. Paradoxical embolism is a condition in which a venous thrombus is embolized into the systemic circulation arteries by a right-to-left heart shunt. Read More

View Article

Download full-text PDF

Source
January 2018
3 Reads

Predictors of thrombolysis in the telestroke and non telestroke settings for hypertensive acute ischemic stroke patients.

BMC Neurol 2018 Dec 21;18(1):215. Epub 2018 Dec 21.

University of South Carolina, School of Medicine-Greenville, Greenville, SC, 29605, USA.

Background: In acute ischemic stroke patients, telestroke technology provides sustainable approaches to improve the use of thrombolysis therapy. How this is achieved as it relates to inclusion or exclusion of clinical risk factors for thrombolysis is not fully understood. We investigated this in a population of hypertensive stroke patients. Read More

View Article

Download full-text PDF

Source
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-
Publisher Site
http://dx.doi.org/10.1186/s12883-018-1204-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302528PMC
December 2018
5 Reads

Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.

J Stroke Cerebrovasc Dis 2019 Mar 17;28(3):815-820. Epub 2018 Dec 17.

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:

Background: Asians with atrial fibrillation carry a higher risk of ischemic stroke than non-Asians even under treatment of nonvitamin K antagonist oral anticoagulants. The purpose of the study was to observe the feasibility of intravenous thrombolytic therapy after administering a reversal agent, idarucizumab, in dabigatran-treated patients with acute ischemic stroke in Taiwan.

Methods: Dabigatran-treated patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) after idarucizumab reversal were enrolled in the retrospective nationwide study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10523057183068
Publisher Site
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.029DOI Listing
March 2019
7 Reads

Implications of the WAKE-UP Trial.

Stroke 2018 Dec;49(12):3115-3117

Stroke Unit and Neurovascular Laboratory, Department of Neurology, University Hospital of Bern, Switzerland (M.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.022436DOI Listing
December 2018
3 Reads

Substantial Improvement of Stroke Care in China.

Stroke 2018 Dec;49(12):3085-3091

From the Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (L.L., J.L., Yilong Wang, Yongjun Wang).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.022618DOI Listing
December 2018
2 Reads

Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction.

QJM 2018 Dec 19. Epub 2018 Dec 19.

Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen University, Xiamen 361005, China.

Aim: Intravenous thrombolysis (IVT) is considered to be the standard reperfusion therapy for acute ischemic stroke (AIS), but its application is limited by high risk of hemorrhagic transformation (HT) after thrombolysis. This study aimed to identify risk factors of HT after IVT.

Methods: Patients with AIS receiving rt-PA thrombolysis from February 2013 to January 2018 were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/qjmed/hcy292DOI Listing
December 2018
7 Reads

Treatment of Simultaneous Thromboembolism of the Right and Left Coronary Arteries with Thrombus Aspiration in a Patient with a Prosthetic Mitral Valve.

J Heart Valve Dis 2018 Jan;27(1):107-109

Department of Cardiology, Şişli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.

Prosthetic heart valve thrombosis is a rare, difficult-to-treat condition that increases morbidity and mortality by leading to systemic embolism. Clinically, it presents mainly in the form of stroke, though an embolism be observed in many systems. Acute coronary syndrome, which is rarely observed in patients with a prosthetic heart valve, mostly occurs as non-ST segment elevation myocardial infarction (MI). Read More

View Article

Download full-text PDF

Source
January 2018
5 Reads

Thrombolytic therapy for pulmonary embolism.

Cochrane Database Syst Rev 2018 12 18;12:CD004437. Epub 2018 Dec 18.

The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.

Background: Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD004437.pub5
Publisher Site
http://dx.doi.org/10.1002/14651858.CD004437.pub5DOI Listing
December 2018
14 Reads

Cerebral venous sinus thrombosis presenting with multifocal intracerebral hemorrhage and subarachnoid hemorrhage: A case report.

Medicine (Baltimore) 2018 Dec;97(50):e13476

Department of Neurology.

Rationale: Multifocal cerebral hemorrhage refers to the cerebral hemorrhage in 2 or more lesions at the same time or 48 h in the brain caused by various causes, which has an acute onset, high mortality rate, and poor clinical treatment effect. Subarachnoid hemorrhage (SAH) is caused by the direct flow of blood into the subarachnoid cavity due to the rupture of the diseased vessels at the base or surface of the brain. Cerebral venous sinus thrombosis (CVST) affects approximately 5 people per million and accounts for approximately 1% of all stroke events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319967PMC
December 2018
3 Reads

Early ST-segment elevation acute myocardial infarction after thrombolytic therapy for acute ischemic stroke: A case report.

Medicine (Baltimore) 2018 Dec;97(50):e13347

National Institute of Neurology and Neurovascular Diseases.

Rationale: Acute ST-segment elevation myocardial infarction (STEMI) is a rare complication of acute ischemic stroke (AIS) during thrombolytic therapy. We report a case of STEMI occurring 40 minutes after thrombolytic therapy for AIS and discuss the possible mechanisms and therapeutic approaches.

Patient Concerns: A 87-year-old woman with a history of arterial hypertension was admitted for acute onset of right-sided limb weakness 2 hours before arrival at the emergency department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320080PMC
December 2018
3 Reads

The Need for Speed.

Circ Cardiovasc Qual Outcomes 2018 Dec;11(12):e005234

Division of Cardiology, University of California, Los Angeles (G.C.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCOUTCOMES.118.005234DOI Listing
December 2018
2 Reads

Effects of Nursing Quality Improvement on Thrombolytic Therapy for Acute Ischemic Stroke.

Front Neurol 2018 29;9:1025. Epub 2018 Nov 29.

Department of Neurology, The First Hospital of Jilin University, Changchun, China.

Intravenous thrombolytic therapy significantly improves the outcomes of acute ischemic stroke patients in a time-dependent manner. The aim of this study was to investigate whether continuous nursing quality improvement in stroke nurses has a positive effect on reducing the time to thrombolysis in acute ischemic stroke. The implementation of nursing quality improvement measures includes establishing full-time stroke nurses, pre-notification by emergency medical services (EMS), stroke team notification protocols, rapid triage, publicity and education, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.01025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281878PMC
November 2018
3 Reads

Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.

Pharmacol Res Perspect 2018 12 5;6(6):e00448. Epub 2018 Dec 5.

Department of Applied Biological Science Tokyo Noko University (Tokyo University of Agriculture and Technology) Tokyo Japan.

SMTP-7 ( triprenyl phenol-7) is a small molecule that promotes thrombolysis and suppresses inflammation possibly through plasminogen modulation and soluble epoxide hydrolase (sEH) inhibition, respectively. Here, we demonstrate an efficacy of SMTP-7 in a severe embolic stroke model in monkeys. The middle cerebral artery was embolized by an autologous blood clot. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/prp2.448
Publisher Site
http://dx.doi.org/10.1002/prp2.448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282002PMC
December 2018
3 Reads

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.

Medicine (Baltimore) 2018 Dec;97(49):e13216

Department of Neurology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi Province, China.

To determine whether glycated hemoglobin and mean arterial pressure (MAP) during thrombolysis are prognostic factors of intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke (AIS).A total of 125 AIS patients, who received rt-PA intravenous thrombolysis in our hospital, were included into the present study, and divided into good prognosis group and poor prognosis group. Univariate and multivariate logistic regression analyses were used to determine the prognostic factors of AIS treated by rt-PA thrombolysis, Spearman correlation analysis was used to analyze the correlation of the accumulated cigarette consumption in the smoking subgroup and glycated hemoglobin in the diabetic subgroup with the prognosis after intravenous thrombolysis and the symptomatic intracranial hemorrhage (sICH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310570PMC
December 2018
2 Reads

Statistical Analysis Plan for EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) trial.

Int J Stroke 2018 Dec 7:1747493018816101. Epub 2018 Dec 7.

1 Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.

Background: EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) is a randomized, multicenter, double-blinded, placebo-controlled phase 3 trial to test the hypothesis of extending the thrombolysis time window to 9 h from stroke onset and in wake-up stroke (WUS) patients.

Objective: To formulate the detailed statistical analysis plan for the EXTEND trial prior to database lock. This statistical analysis plan is based on the published and registered EXTEND trial protocol and is developed by the blinded steering committee and management team. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1747493018816101DOI Listing
December 2018
2 Reads

Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke.

Sci Rep 2018 Dec 11;8(1):17770. Epub 2018 Dec 11.

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan.

Although the regulation of post-ischemic inflammation is an important strategy to treat ischemic stroke, all clinical trials have failed to show its efficacy. To solve the problem, we previously developed a novel partial peptide of RANKL, microglial healing peptide 1 (MHP1), which could reduce ischemic injury by inhibiting Toll-like receptor (TLR) induced inflammation. However, optimization of the peptide was necessary to increase the stability and efficacies for clinical use. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-35898-z
Publisher Site
http://dx.doi.org/10.1038/s41598-018-35898-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290023PMC
December 2018
8 Reads

Enhancing Base Excision Repair of Mitochondrial DNA to Reduce Ischemic Injury Following Reperfusion.

Transl Stroke Res 2018 Dec 8. Epub 2018 Dec 8.

Exscien Corp, Mobile, AL, 36688, USA.

We hypothesize that enhancing mitochondrial base excision repair (BER) capability in brain will reduce reperfusion-associated ischemic brain injury. Post-stroke reperfusion was modeled in mice via transient filament occlusion of the middle cerebral artery (60 min) (transient MCAO). Administration of a TAT-modified form of a DNA glycosylase (EndoIII) following reperfusion of the brain reduced resultant brain infarct volume. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12975-018-0680-5
Publisher Site
http://dx.doi.org/10.1007/s12975-018-0680-5DOI Listing
December 2018
4 Reads

Successful mechanical thrombectomy in stroke with thrombolysis-associated intracerebral hemorrhage-a case report.

J Stroke Cerebrovasc Dis 2019 Feb 24;28(2):285-287. Epub 2018 Oct 24.

Department of Neurology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address:

Background: Intravenous thrombolysis and mechanical thrombectomy are the standard of care for patients with acute ischemic stroke with large vessel occlusion. Intracerebral hemorrhage is a main complication of intravenous thrombolysis, however, no data are available on the efficacy and safety of mechanical thrombectomy in patients with thrombolysis-associated intracerebral hemorrhage. This constellation is expected to become more frequent as increasing numbers of patients are treated under the drip-and-ship paradigm. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10523057183056
Publisher Site
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.045DOI Listing
February 2019
5 Reads
1.993 Impact Factor

Thromboembolic Complications Following Tissue Plasminogen Activator Therapy in Patients of Acute Ischemic Stroke - Case Report and Possibility for Detection of Cardiac Thrombi.

Open Med (Wars) 2018 19;13:551-555. Epub 2018 Nov 19.

Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kamimachi, Itabashi-ku, Tokyo Japan.

Many reports focus on the probability of intracranial hemorrhage as a complication after recombinant tissue plasminogen activator (rt-PA) therapy. However, thromboembolic complications are not well discussed. We experienced a case in which severe thromboembolic complications occurred in the right radial and right ulnar artery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/med-2018-0081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272048PMC
November 2018
3 Reads